binx health partners with global healthcare leader, McKesson, for National Launch of the FDA-cleared binx io platform

binx molecular point-of-care platform poised to transform care for chlamydia and gonorrhea, the two most tested for sexually-transmitted infections

Boston, MA, February 16, 2021

A first-of-kind FDA-cleared infectious disease platform, the binx io provides results in about thirty minutes, which enables diagnosis and treatment of chlamydia (CT) and gonorrhea (NG) to take place in a single visit. The binx io’s test performance has been demonstrated to be on par with central-laboratory testing.

Today, about thirty-five million CT/NG tests are processed at central laboratories, with virtually all patients leaving a clinic before results are ready. Under this traditional care model, up to 40%[1] of patients who are subsequently determined to be positive do not return for treatment once they leave the clinic, leading to further infection spread and comorbidities.

The binx io is poised to change all of that, by delivering results within the time window of a typical OB-GYN visit. Initial distribution of the binx io will be into settings that are certified to perform moderate or high complexity diagnostic tests under the Clinical Laboratory Improvement Amendments (CLIA). The binx io platform also may be used in satellite point-of-care (POC) settings designated under such moderate or high complexity certificates. binx has also completed its CLIA waiver study and submitted a request to the Food and Drug Administration (FDA) in 2020 to classify the platform as CLIA waived, which, upon FDA clearance, will enable distribution to the 200,000+ CLIA-waived locations nationwide.

“At binx we consider evidence-based care and consumer convenience central to all we do,” said Jeffrey Luber, binx health’s Chief Executive Officer. “Today’s announcement is a win-win-win for clinics, patients and the public health and we are especially proud of this new distribution partnership for national reach.”

binx health has partnered with global healthcare leader McKesson for the sale and distribution of the binx io platform.

For more information about binx io, visit or contact

2021-03-03T17:21:54+00:00March 3rd, 2021|

Symetrica appoints John Zangardi, a former advisor to the US Secretary of Defense for Information Management / Information Technology to its Board of Directors

Symetrica Inc, an innovative, leading radiation detection and identification business in Massachusetts has announced a material business impact from the appointment of John Zangardi, a former advisor to the US Secretary of Defense for Information Management / Information Technology as a Non-Executive Director to the Symetrica Board. Symetrica Inc. operates internationally and has successfully provided the Homeland Security and Military radiation detection market sectors with a wide range of innovative solutions for over 10 years.


2021-03-03T17:33:00+00:00March 1st, 2021|

Micrima appoints Adrain Waller as CEO

Micrima is pleased to announce after a professional search to find a new CEO with the right blend of MedTech and commercial experience, we have appointed Adrian Waller who will start on the 1st Jan 2021. Adrian has extensive Medical device experience together with a technical background (aerospace engineering) and for the last six years has been General Manager of Fujifilm Medical`s diagnostic medical-imaging business in the UK. During that time he was responsible for all UK activities, including commercial which grew significantly, in all areas, under his leadership. Prior to Fujifilm, Adrian spent three years with GE Healthcare where he was brought in to assist and restructure the team as they exited the National Programme for IT (NPfIT) before helping them commercialise a range of very specialised IT Solutions for the MedTech sector.

Adrian said in a brief statement to investors “I’m incredibly excited about joining Micrima at such a key stage of its development.  The potential of the MARIA® system to transform the diagnosis of breast cancer is clear and the opportunity to work with the team to accelerate the products adoption and continued development was something that I had to get involved with.  I’m really looking forward to joining the team in the new year and using my market knowledge, network, and business management skills to help Micrima make a difference to the ~600k ladies that die of breast cancer, every year” We look forward to a more in-depth article with Adrian when he formally joins the company in 2021

2021-03-03T17:21:02+00:00February 1st, 2021|

New York Film Academy Selects binx health for COVID-19 Testing, Creating Instant Platform for Broad Health Offerings Across Multiple Campuses

binx health is excited to announce it will provide university-wide COVID-19 testing for the New York Film Academy (NYFA), among the most highly regarded visual and performing arts colleges in the world. The binx platform will enable at-home, in-dorm and on campus specimen collection, providing healthcare convenience for NYFA students, faculty and staff at campuses in New York, Los Angeles and Miami.

With US colleges representing 19 of the top 25 vectors of transmission of COVID-19, the binx solution is being deployed across campuses to keep students and faculty safe. As California, Florida and New York currently comprise three of the four states with the highest daily case rates in the country, and are locations that include NYFA campuses, there continues to be a strong need for the convenient, high quality testing, which binx is offering to NYFA and to institutional partners globally.

“At NYFA, our priority is to create a safe and healthy learning and working environment for our students, faculty and staff. With a geographically diverse student and employee base, it was of the utmost importance that our community has access to high quality, accurate, and accessible testing and easy-to-use sample collection, a solution NYFA will be employing on campus and that can also be offered conveniently at-home and in-dorm,” said NYFA President, Michael Young. “With the binx COVID-19 testing solution now in place, our community has the opportunity to easily expand and evaluate other health testing using at-home collection kits with the support and solutions of binx health.”

“We applaud NYFA for their commitment to care, and to their communities, and we look forward to partnering with them across their wellness initiatives,” said Jeffrey Luber, binx Chief Executive Officer.

2021-03-03T15:02:03+00:00January 26th, 2021|

VQ Communications, the Chippenham, UK based supplier of Video Conferencing Management Software is now a CISCO Solutions Plus Partner

VQ is now a Cisco Solutions Plus Partner

This is a big day for VQ and I’m really pleased and excited to announce that VQ Conference Manager can now be purchased through Cisco. Thank you to everybody at Cisco who made it possible and championed VQ. Thank you to our partners and customers for their risk taking and votes of confidence over the years leading up to this result.

This isn’t all about VQ; the real message is CMS plus VQ and enabling enterprise wide audio and video conferencing. For example, over the last couple of days I’ve seen data from 4 large CMS/VQ systems with in-call participant counts of 8000+, 7000+, 3000+ and 1000+ for large periods of the day; that’s over 20,000 people in call on just 4 of the 150+ VQ systems in the field. The numbers clearly show how CMS based systems deliver services on a completely different scale from previous bridge generations. The CMS platform is underpinning organizations, delivering the promise of the digital workplace and enabling a degree of business as usual in these difficult times.

Secure, VQ Conference Manager is mostly installed as an on-premises solution although we also have a number of service provider customers and are starting to see secure cloud offerings being evaluated. Customers are located globally and include a wide range of categories including enterprise, health, government and defence.

Our roadmap looks great and should start to see the next round of changes from mid-May targeted at enabling customers transitioning to CMS as their Codians go end-of-life.

We look forward to working with you.

Take care,


2021-03-03T17:52:18+00:00April 8th, 2020|

Binx Health Receives FDA 510(k) Clearance for Rapid Point of Care Platform

August 12, 2019 (BOSTON) PR NEWSWIRE – binx health, the pioneer in anywhere, anytime testing for women’s health, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its first-of-kind, highly sensitive and specific, molecular point-of-care (POC) diagnostic testing platform, the binx io®.  The binx io platform is a rapid, qualitative, fully-automated test, designed to be easy to use, and intended for use in POC or clinical laboratory settings, providing the world’s first sample-to-answer result in about 30 minutes for the detection of chlamydia (CT) and gonorrhea (NG)—the two most tested-for STIs globally. In the Company’s recently completed 1,523-person, multi-center clinical study, 96% of patient samples were processed on the binx io by non-laboratorians in a POC setting.


2021-03-03T15:02:26+00:00September 19th, 2019|

Symetrica wins the Venture category at the BVCA South West Management Team Awards 2017

Symetrica have been announced as the winner of the Venture Category at the British Private Equity & Venture Capital Association’s (BVCA) South West Management Team Awards 2017. Now in their ninth year, the BVCA Management Team Awards recognise and reward brilliant businesses up and down the country that are backed by UK private equity and venture capital investors.

The BVCA’s judges’ commented: “Symetrica has been a pioneer in its radiation detection technology and now has a leading position in homeland security. The judges were impressed with the way Heddwyn Davies had grasped this opportunity in 2016, driving a fourfold increase in sales, notably breaking into the US market, while at the same time bringing out a handheld version of the technology.”

Symetrica will now go forward into the national final to compete against the other UK regions before the national winners are announced at the BVCA Gala Dinner on 30 November in London.

BVCA Management Team Awards

2019-04-10T17:40:27+00:00May 5th, 2017|

Atlas Genetics Gains EU CE Approval for First Product

Approval of Chlamydia test for marketing and sale in Europe

Atlas Genetics Ltd, the Bath, UK based, ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces that it has received approval to CE Mark its Chlamydia trachomatis (CT) test to be launched on the Company’s io® platform.  By meeting the requirements of the IVD Directive (98/79/EC), the CT test is now cleared for sale within the European Union.

The launch of the io® CT test signals a new era in ultra-rapid molecular diagnostics.  This is the first molecular POC test for a Sexually Transmitted Infection (STI) to enter the market, capable of delivering test results in just 30 minutes.  With the speed and accuracy of the io® CT product, the testing and treatment of patients within a single, brief visit to the clinic now becomes a reality.


2016-02-09T10:06:50+00:00February 9th, 2016|

Sky partners with Object Matrix

Object Matrix, the trusted storage partner to the media and entertainment industries, today announces that Sky, Europe’s leading entertainment company with over 21 million customers, has integrated MatrixStore object storage into Avid Interplay production workflows at its headquarters in London.

Sky is Europe’s leading investor in television content, with a combined programming budget of £4.9bn, commissioning its own original programming and entering into strategic partnerships to deliver the best possible TV viewing experience for customers. With production infrastructure often used to capacity, the Sky production team looked to find a solution that could not only scale into future workflows but also take the strain off the editing storage with seamless integration into current workflows.


2016-05-30T15:33:34+00:00February 2nd, 2016|

Symetrica’s Radiation Detection and Identification Technology to be deployed by US Department of Homeland Security

Symetrica has announced that its patented radiation detection and identification technology will be deployed in the latest Handheld Radioisotope Identification Devices (RIIDs) that Smiths Detection Inc. has agreed to supply to the U.S. as part of a contract with the Department of Homeland Security (DHS). Symetrica’s Discovery Technology is at the heart of the Smiths Detection RadSeeker handheld radiation detectors for which the DHS Domestic Nuclear Detection Office (DNDO) recently awarded an IDIQ (indefinite delivery/indefinite quantity) contract with a maximum value of $143 million for the technology, its maintenance and associated training.


2019-04-10T17:40:28+00:00January 28th, 2016|

Technology Venture Partners appoints Richard Green as Non-executive Chairman

Technology Venture Partners the technology venture capital firm has announced the appointment of Richard Green as Non-executive Chairman.

Richard Green joined Kleinwort Benson Development Capital in 1988 and was a founder in 2001 of the spin-out business which became August Equity LLP, where he was the Managing Partner until 2009 and then Chairman until his retirement in April 2014.  He is a past chairman of the British Venture Capital Association and is currently a non-executive director of AIM-quoted Qannas Investments Limited, a non-executive director of Northern Venture Trust PLC, a member of the Advisory Board of Finance for Business North East and a member of the Advisory Committee of the European Investment Bank’s Growth Finance Initiative.


2019-04-10T17:40:28+00:00July 16th, 2015|

Symetrica Appoints David Price As Chairman

Symetrica, the Technology Venture Partners portfolio company providing radiation detection solutions company has announced the appointment of David Price as Non-executive Chairman.

David Price was formerly CEO of Chemring Group plc, the FTSE 250 listed with revenues of £600m. Chemring is a specialist manufacturer of expendable countermeasures, advanced electronics and energetic materials for the global defence, security and safety markets. Prior to Chemring, David was MD of Rolls Royce Naval Marine, a division supplying propulsion systems, products & services to 59 navies for both submarine and surface ship applications. Naval Marine is a global business with a turnover of over £450m per year and employing 2900 staff. It undertook the design authority role for all Royal Navy nuclear reactor systems and manufactured all of the key components for the Pressurised Water Reactor. (more…)

2016-01-28T12:10:00+00:00June 23rd, 2015|

Atlas completes $20 million Series C fundraising

Funds to accelerate global launch of Atlas io® molecular testing system

Bath, UK, 29 January, 2015. Atlas Genetics Ltd (“Atlas” or the “Company”), the ultra-rapid ‘test and treat’ molecular diagnostics company, today announces the completion of a Series C financing, raising $20 million from a syndicate including existing investors and one new investor, RMI Partners. New investor, RMI Partners, is a global life sciences venture capital firm, the largest in Eastern Europe. Existing investors include Novartis Venture Funds, Consort Medical plc, Johnson & Johnson Innovation – JJDC, Inc., LSP, BB Biotech Ventures and Technology Venture Partners. This newly announced financing follows on from the previously announced Series B fundraising of $25 million. (more…)

2015-06-23T13:21:26+00:00January 29th, 2015|

Bristol venture team set up Technology Venture Partners in spin-out from YFM Equity Partners

The Bristol team of YFM Equity Partners have taken over managing the South West Ventures Fund through a newly formed independent venture capital fund manager, Technology Venture Partners.

The South West Ventures Fund was established as one of the UK’s nine Regional Venture Capital Funds to invest up to £2m of risk capital into high growth small businesses. The fund is now fully invested and the portfolio includes Dynmark, a cloud based mobile intelligence and messaging platform and Micrima, which has developed innovative technology for breast cancer screening based on radiowaves instead of X-rays.

The spin-out will see the South West Ventures Fund continue to be managed by the three founding partners of Technology Venture Partners, Peter Davies, Nick Simmonds and Julian Dennard. Technology Venture Partners will focus on investing in emerging UK technology companies.


2019-04-10T17:40:28+00:00May 23rd, 2014|
Go to Top